Search research articles
Contact Us
Filters
Showing results (201-210 of 257) with videos related to
Page
of 26
Sort By:
Blood
|
January 25, 2012
IMWG consensus on maintenance therapy in multiple myeloma
Heinz Ludwig, Brian G M Durie, Philip McCarthy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2014
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death
Philippe Moreau, Michele Cavo, Pieter Sonneveld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 27, 2016
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome
Bruno Royer, Stéphane Minvielle, Momar Diouf, et al.
Leukemia
|
May 23, 2018
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
Charles Dumontet, Cyrille Hulin, Meletios A Dimopoulos, et al.
Blood
|
January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
Antonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
Blood
|
July 21, 2021
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Michele Cavo, Jesus San-Miguel, Saad Z Usmani, et al.
The Lancet. Oncology
|
December 17, 2015
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A Dimopoulos, Philippe Moreau, Antonio Palumbo, et al.
The Lancet. Oncology
|
October 16, 2021
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Thierry Facon, Shaji K Kumar, Torben Plesner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 26, 2013
Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience
Hervé Avet-Loiseau, Cyrille Hulin, Loic Campion, et al.
The New England Journal of Medicine
|
March 1, 2002
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
Hagop Kantarjian, Charles Sawyers, Andreas Hochhaus, et al.
Page
of 26
Search research articles
Search
Showing results (201-210 of 257) with videos related to
Sort By:
Page
of 26
Blood
|
January 25, 2012
IMWG consensus on maintenance therapy in multiple myeloma
Heinz Ludwig, Brian G M Durie, Philip McCarthy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2014
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death
Philippe Moreau, Michele Cavo, Pieter Sonneveld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 27, 2016
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome
Bruno Royer, Stéphane Minvielle, Momar Diouf, et al.
Leukemia
|
May 23, 2018
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
Charles Dumontet, Cyrille Hulin, Meletios A Dimopoulos, et al.
Blood
|
January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
Antonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
Blood
|
July 21, 2021
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Michele Cavo, Jesus San-Miguel, Saad Z Usmani, et al.
The Lancet. Oncology
|
December 17, 2015
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A Dimopoulos, Philippe Moreau, Antonio Palumbo, et al.
The Lancet. Oncology
|
October 16, 2021
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Thierry Facon, Shaji K Kumar, Torben Plesner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 26, 2013
Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience
Hervé Avet-Loiseau, Cyrille Hulin, Loic Campion, et al.
The New England Journal of Medicine
|
March 1, 2002
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
Hagop Kantarjian, Charles Sawyers, Andreas Hochhaus, et al.
Page
of 26